Compare Repligen Corporation Common Stock (RGEN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs TG Therapeutics Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while TG Therapeutics Inc trades at $54.41 (market cap $8.32B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is more actively traded (1,259,263 versus 1,001,204). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and TG Therapeutics Inc for 16 Days on average.
| RGEN | TGTX | |
|---|---|---|
Market Cap | $11.14B | $8.32B |
Volume | 1,259,263 | 1,001,204 |
Sector | Health | Health |
52-Week High | $194.57 | $59.06 |
52-Week Low | $102.87 | $26.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $11.02B | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TG Therapeutics trades at $54.34, down 1.68% today, with a bullish technical outlook supported by moving averages. The company shows strong profitability with 55.22% net income margin and 100.28% ROE, though recent quarters saw EPS misses. Revenue guidance for 2026 is raised to $950M for BRIUMVI, with institutional buying interest from major banks. A shareholder investigation by Kuehn Law presents legal overhang.
Outlook remains positive given analyst consensus target of $80.50 (48% upside) and buyout speculation. Key risks include ongoing legal scrutiny and reliance on BRIUMVI's market share growth. The stock offers growth potential but requires monitoring of legal developments and competitive pressures in the MS treatment space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
